Physician profile
Michael D Merkin
NPI 1669548079
$12,246.30
in general payments reported to CMS, 2019-2025
64 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $1,651 · 2021: $1,851 · 2022: $1,960 · 2023: $1,894 · 2024: $1,567 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,232.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,820.01 | 2019-2025 | |
| Biogen, INC. | $1,497.18 | 2019-2025 | Vumerity, Avonex, Tysabri |
| Abbvie INC. | $1,017.53 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $562.65 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $488.15 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Eisai INC. | $393.82 | 2019-2025 | |
| Mdd US Operations, LLC | $362.50 | 2021-2025 | Apokyn, Xadago, Apokyn |
| Genentech USA, INC. | $356.52 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $329.17 | 2019-2024 | Uplizna |
| Amneal Pharmaceuticals LLC | $319.97 | 2020-2025 | Rytary, Crexont, Brekiya |
| Neurocrine Biosciences, INC. | $318.44 | 2019-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $308.24 | 2020-2025 | Zeposia |
| Lundbeck LLC | $308.14 | 2022-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $266.14 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Emd Serono, INC. | $265.79 | 2019-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Merkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.